425: Inmagene Reports Positive Phase 2a Results for Atopic Dermatitis Treatment IMG-007

Inmagene Biopharmaceuticals announced positive topline results from a Phase 2a trial of IMG-007, showing significant reduction in eczema severity and a favorable safety profile for the treatment of atopic dermatitis.

Summary

• Inmagene Biopharmaceuticals has released positive topline results from a Phase 2a trial of their drug IMG-007 for treating moderate-to-severe atopic dermatitis.
• The trial showed a 77% mean reduction in the eczema area and severity index (EASI) after four weeks of treatment.
• 54% of patients achieved an EASI-75 response, meaning a 75% or greater improvement in their condition, by week 16.
• The drug also demonstrated durable inhibition of inflammatory markers for up to 24 weeks.
• A Phase 1 study of a subcutaneous (SC) formulation of IMG-007 showed an extended half-life of approximately 35 days.
• IMG-007 was generally well-tolerated, with no serious adverse events, treatment discontinuations, or treatment-related adverse events reported.
• The company plans to initiate a Phase 2b dose-finding study with the SC formulation in Q1 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a good safety profile and a potential for less frequent dosing, which is a significant advantage. The mention of a potential merger and capital raise adds a slight element of uncertainty, but the overall tone is very positive.

Positives

• IMG-007 demonstrated a significant reduction in eczema severity, with a 77% mean reduction in EASI.
• The drug showed a strong EASI-75 response rate of 54% at week 16.
• The extended half-life of the subcutaneous formulation of approximately 35 days could allow for less frequent dosing.
• The drug was well-tolerated with no serious adverse events reported.
• The drug's mechanism of action blocks OX40/OX40L signaling without depleting T cells, potentially improving safety.

Negatives

• Injection site reactions were reported, although they were mild and more frequent in the placebo group.

Risks

• The results are from a Phase 2a trial and may not be indicative of future results.
• There have been no head-to-head trials comparing IMG-007 to other similar drugs.
• The company faces risks associated with clinical development and regulatory approval.
• There are risks related to obtaining sufficient capital to continue development, including the proposed merger with Ikena Oncology, Inc.

Future Outlook

Inmagene plans to initiate a Phase 2b dose-finding study with IMG-007's subcutaneous formulation in Q1 2025 and explore long dosing intervals for maintenance therapy in atopic dermatitis and other potential indications. The company also has another drug, IMG-004, ready for Phase 2 development.

Management Comments

• Jonathan Wang, founder, Chairman and CEO of Inmagene, stated that IMG-007's extended half-life and sustained efficacy will enable the exploration of long dosing intervals.
• Yufang Lu, M.D., Ph.D., Chief Medical Officer of Inmagene, noted that the ADCC silencing of IMG-007 has retained the desired biological activity of OX40 blockade while improving tolerability.

Industry Context

The development of IMG-007 addresses the need for more convenient and effective treatments for atopic dermatitis, a chronic condition requiring long-term management. The extended half-life of IMG-007 could provide a competitive advantage over existing biologics that require frequent injections.

Comparison to Industry Standards

• The reported EASI-75 response of 54% at week 16 is within the range shown by other investigational OX40/OX40L-targeting mAbs with longer duration (at least 16 weeks) of treatments.
• The extended half-life of 34.7 days for the SC formulation is substantially longer than that of other OX40/OX40L mAbs in clinical development, potentially allowing for less frequent dosing.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising clinical results.
• Patients with atopic dermatitis may benefit from a new treatment option with less frequent dosing.
• Employees of Inmagene may be positively impacted by the progress of the company's pipeline.

Next Steps

• Initiation of a Phase 2b dose-finding study with IMG-007's SC formulation in Q1 2025.
• Exploration of long dosing intervals for maintenance therapy in AD and other potential indications.

Key Dates

Keywords

IMG-007, Atopic Dermatitis, OX40, Monoclonal Antibody, EASI, Phase 2a Trial, Inmagene, Immunological Diseases, Inflammatory Diseases, Subcutaneous Formulation